항암제와 한약재의 병용투여 시 암세포 증식억제 효과에 대한 국내 실험연구 문헌고찰

이지은,최진용,한창우,최준용,박성하,김소연,Lee, Ji Eun,Choi, Jin Yong,Han, Chang Woo,Choi, Jun Yong,Park, Seong Ha,Kim, So Yeon 대한한의학방제학회 2017 大韓韓醫學方劑學會誌 Vol.25 No.3

Objective : In this study, we searched the experimental research about combined treatment of anticancer drug and herbal medicine for killing or inhibiting proliferation of Cancer cells searched in OASIS and KISS. This study aimed to analyze the experimental research paper about anticancer drug combined treatment with herbal medicine. Methods : We collected the research paper including killing or inhibiting proliferation of Cancer cells in OASIS and KISS using keyword anticancer drug with herbal medicine, tumor suppressor with herbal medicine, inhibition of Cancer with herbal medicine and combined treatment with herbal medicine. Assorting by cancer cells, we analyzed experimental results cancer cell viability, anticancer drug dosage, tumor weight and survival rate. Also, we checked the effects of herbal medicine on cancer and additive effect reducing side effect of anticancer drug. Results : Total 45 studies were selected. 38 studies reported combined treatment of anticancer drug and herbal medicine was more effective than only anticancer drug. The death of cancer cells was synergistically induced by the cotreatment of anticancer drug and herb extracts. The studies suggest that the cotreatment of anticancer drug and herb extracts could reduce side effect of anticancer drug. In addition, some studies reported cotreatment mechanism like apoptotic death signal processes. In combined treatment of anticancer drug and herb extracts, The expression of Fas/Fas L, Bax, Bcl2, Caspase-3 etc.. was markedly increased in cancer cells. Conclusions : Our results suggest that anticancer drug combined treatment with herbal medicine could be efficient for killing or inhibiting proliferation of cancer cells. However, this paper had some limitation as follows: First, collected studies have been published only for korean journal. Second, results of research and effects of combined treatment are not collected objectively. To solve these problems, more objective and balanced studies should be performed.

Anticancer activity of drug-loaded calcium phosphate nanocomposites against human osteosarcoma

손경단,김영진 한국생체재료학회 2017 생체재료학회지 Vol.21 No.3

Background: Calcium phosphate (CaP) based nanoparticles are considered to be ideal drug carriers for delivery of anticancer drugs because of their excellent biocompatibility and pH responsiveness. However, CaP nanoparticles have the problems of limited drug load capacity, initial burst release, and short-term release. Thus, we prepared the CaP nanocomposites containing anticancer drug such as caffeic acid (CA-NP), chlorogenic acid (CG-NP), or cisplatin (CP-NP) in the presence of alginate as a polymer template to control the release rate of drugs. Results: The drug-loaded CaP nanocomposites exhibited spherical shape with a size of under 100 nm and the size of nanocomposites was hardly affected by the addition of drug. UV-visible spectroscopic analysis confirmed the insertion of drug into the CaP nanocomposites. These nanocomposites showed an initial burst release of drug, followed by a prolonged release, in which the release profile of drugs was depended on the solution pH. In addition, the drug-loaded CaP nanocomposites revealed anticancer activity on human osteosarcoma in a manner dependent on concentration of drugs and time. Conclusions: The drug-loaded CaP nanocomposites can contribute to the development of a new generation of controlled drug release carriers for chemotherapy of cancers.

일 종합병원의 항암제 취급 간호사의 항암제 안전관리 교육요구도

하부영,이인숙 (사)위기관리이론과실천 2023 Crisisonomy Vol.19 No.3

This research investigated clinical nurses’ educational needs for safe anticancer drug management. A cross-sectional descriptive study involving 225 clinical nurses who responded to self-reporting questionnaires was conducted from May 26 to June 20, 2021. Descriptive statistics, a paired t-test, and demand analysis utilizing Borich analysis and the Locus for Focus model were used to evaluate the data. As a results, the categories with the highest priority were “coping with exposure to anticancer drugs,” “environmental control of the handling of anticancer drugs,” “safe administration of an anticancer drug,” “handling of patients’ blood, body fluids, and excretion,” “fulfilling education on the safe management of anticancer drugs,” and “using personal protective equipment.” These findings will help develop educational programs for clinical nurses who deal with anticancer drugs. Future studies should concentrate on developing and evaluating a program for the safe management of anticancer drugs.

AttDRP: 주의집중 메커니즘 기반의 항암제 약물 반응성 예측 모델

최종환,서상민,박상현 한국정보과학회 2021 정보과학회논문지 Vol.48 No.6

Resistance to anti-cancer drugs makes chemotherapy ineffective for cancer patients. Drug resistance is caused by genetic alterations in cancer cells. Many studies have investigated drug responses of diverse cancer cell lines to various anti-cancer drugs to understand drug response mechanisms. Existing studies have proposed machine learning models for drug response prediction to find effective anti-cancer drugs. However, currently there are no models to learn the relationship between anticancer drugs and genes to improve the prediction accuracy. In this paper, we proposed a predictive model AttDRP that could identify important genes associated with anti-cancer drugs and predict drug responses based on identified genes. AttDRP exhibited better predictive accuracy than existing models and we found that the attention scores of AttDRP could be effective tools to analyze molecular structures of anticancer drugs. We hope that our proposed method would contribute to the development of precision medicine for effective chemotherapy. Resistance to anti-cancer drugs makes chemotherapy ineffective for cancer patients. Drug resistance is caused by genetic alterations in cancer cells. Many studies have investigated drug responses of diverse cancer cell lines to various anti-cancer drugs to understand drug response mechanisms. Existing studies have proposed machine learning models for drug response prediction to find effective anti-cancer drugs. However, currently there are no models to learn the relationship between anticancer drugs and genes to improve the prediction accuracy. In this paper, we proposed a predictive model AttDRP that could identify important genes associated with anti-cancer drugs and predict drug responses based on identified genes. AttDRP exhibited better predictive accuracy than existing models and we found that the attention scores of AttDRP could be effective tools to analyze molecular structures of anticancer drugs. 암환자 중 일부는 항암제에 대한 약물 저항성을 보여 약물을 이용한 항암치료를 어렵게 만든다. 약물 저항성은 암세포의 유전체 이상에 기인하는 것으로 밝혀져, 암세포주 및 항암제에 대한 약물 반응성 데이터를 분석하는 연구가 활발히 이루어지고 있다. 기존 연구들은 기계학습을 이용하여 약물 민감성 또는 저항성을 예측하는 모델을 여럿 제안하였으나, 항암제와 유전자의 관계를 학습하는 모델의 부재로 인하여 예측 정확도 향상을 위한 여지가 남아있었다. 본 논문에서는 주의집중 메커니즘을 활용하여 항암제 관련 유전자들을 식별하고, 그러한 유전자들 정보에 기반하여 항암제 반응성을 예측하는 AttDRP를 제안한다. 제안하는 모델은 CCLE 데이터에서 기존 모델들보다 높은 예측 정확도를 보여주었고, AttDRP이 학습한 주의집중 스코어가 항암제의 분자구조 분석에 효과적으로 활용될 수 있음을 확인하였다.

Drug-eluting stent covered with medium chain fatty acid for enhancing penetration of anticancer drugs

박진환,정두용,이돈행,이동기,나건 한국공업화학회 2020 한국공업화학회 연구논문 초록집 Vol.2020 No.-

Non-vascular drug-eluting stent (DES) has been considered a remarkable medical device for the treatment of bile duct, gastrointestinal stenosis. However, non-vascular DESs could not be commercialized due to low permeability and diffusion of eluted drug in certain tissues. We developed DES containing medium chain fatty acids (MCFA) as an enhancer of permeability for anticancer drug. MCFA has been used an enhancer in order to promote the absorption of various drugs such as heparin, insulin, and ampicillin. In DES incorporated with MCFA and anticancer drug, its exposed surface morphology and drug release profile were demonstrated in vitro. Also, drug penetration efficacy was higher than conventional DESs. Consequently, this platform has noticeable potential for local effective stent in anticancer therapy.

Gemcitabine-incorporated polyurethane films for controlled release of an anticancer drug

Seong Hoon Choi,Il-Hoon Cho,박상수 한국생체재료학회 2019 생체재료학회지 Vol.23 No.4

Background: Local delivery of anti-cancer drugs through a stent is a very promising and anticipated treatment modality for patients who have obstructions in their gastrointestinal tract with malignant tumors. Anticancer drug release via stents, however, needs to be optimized with respect to drug delivery behavior for the stents to be effective for prolonged containment of tumor proliferation and stent re-obstruction. Local stent-based drug delivery has been tested using an effective anti-cancer drug, gemcitabine, but the release from the stent-coated polyurethane films is often too fast and the drug is depleted from the coated film virtually in a day. Methods: To moderate the drug release from a polyurethane film, a gemcitabine-incorporated polyurethane film was enveloped with a pure polyurethane film, with no drug loading, and with a silicone film by solution casting after activation of the silicone film surface with plasma treatment. Results: The pure polyurethane barrier film was effective; the interface of the two were indistinguishable on scanning electron microscopy, and the initial burst, i.e., the cumulative release in a day, decreased from 90 to 26%. The silicone film barrier, on the other hand, was defective as voids were seen using a scanning electron microscope, and micro-separation of the two layers was observed after the film was immersed in phosphatebuffered saline for 1 day during the in vitro drug release study. Conclusions: Enveloping a gemcitabine-releasing polyurethane film with a homo-polymer barrier film was quite effective for moderating the initial burst of gemcitabine, thus, prolonging the release time of the drug. Enveloping the polyurethane film with a silicone film was also possible after plasma treatment of the silicone film surface, but the two films eventually separated in the aqueous environment. More studies are needed to tune the drug release behavior of gemcitabine from the stent covering film before attempting a clinical application of an anti-cancer drug releasing stent.

Nanostructured surfaces for analysis of anticancer drug and cell diagnosis based on electrochemical and SERS tools

El-Said Waleed A.,Yoon Jinho,최정우 나노기술연구협의회 2018 Nano Convergence Vol.5 No.11

Discovering new anticancer drugs and screening their efficacy requires a huge amount of resources and time-consuming processes. The development of fast, sensitive, and nondestructive methods for the in vitro and in vivo detection of anticancer drugs’ effects and action mechanisms have been done to reduce the time and resources required to discover new anticancer drugs. For the in vitro and in vivo detection of the efficiency, distribution, and action mechanism of anticancer drugs, the applications of electrochemical techniques such as electrochemical cell chips and optical techniques such as surface-enhanced Raman spectroscopy (SERS) have been developed based on the nanostructured surface. Research focused on electrochemical cell chips and the SERS technique have been reviewed here; electrochemical cell chips based on nanostructured surfaces have been developed for the in vitro detection of cell viability and the evaluation of the effects of anticancer drugs, which showed the high capability to evaluate the cytotoxic effects of several chemicals at low concentrations. SERS technique based on the nanostructured surface have been used as label-free, simple, and nondestructive techniques for the in vitro and in vivo monitoring of the distribution, mechanism, and metabolism of different anticancer drugs at the cellular level. The use of electrochemical cell chips and the SERS technique based on the nanostructured surface should be good tools to detect the effects and action mechanisms of anticancer drugs.

Development of Dual-Arm Anticancer Drug Compounding Robot and Preparation System with Adaptability and High-Speed

Nam, Giyoon,Kim, Young Joo,Kim, Yun Jung,Kim, Yeoun Jae,Seo, Jung Ae,Kim, Kyunghwan,Kim, Kwang Gi International Society for Simulation Surgery 2016 Journal of International Society for Simulation Su Vol.3 No.2

Aim Robots are able to increase safety for pharmacy staff as separating from toxicity of anti-cancer drugs. For patient safety, it would provide right dose of the drugs. Additionally, it can reduce price of the drugs. Therefore, in this study, a novel compounding anticancer drugs robot system (Dupalro) was developed. Methods We used the robot system, Motoman dual-arm robot from YASKAWA, Japan and medications which are adapted for the robot were constructed. In order to develop a process of compounding anticancer drugs, information about five medications that are required to make anticancer drugs in hospitals was used. Results System for the five types of medications was constructed, and relating procedures for anticancer drugs compounding robot were developed. Conclusion Dupalro successfully was able to not only provide incremental safety and efficiency for both patients and pharmacy staff, but also decrease price of anticancer drugs.

Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer

Gurunathan, Sangiliyandi,Kang, Min-Hee,Qasim, Muhammad,Kim, Jin-Hoi MDPI 2018 INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Vol.19 No.10

<P>Cancer represents a group of heterogeneous diseases characterized by uncontrolled growth and spread of abnormal cells, ultimately leading to death. Nanomedicine plays a significant role in the development of nanodrugs, nanodevices, drug delivery systems and nanocarriers. Some of the major issues in the treatment of cancer are multidrug resistance (MDR), narrow therapeutic window and undesired side effects of available anticancer drugs and the limitations of anticancer drugs. Several nanosystems being utilized for detection, diagnosis and treatment such as theranostic carriers, liposomes, carbon nanotubes, quantum dots, polymeric micelles, dendrimers and metallic nanoparticles. However, nonbiodegradable nanoparticles causes high tissue accumulation and leads to toxicity. MDR is considered a major impediment to cancer treatment due to metastatic tumors that develop resistance to chemotherapy. MDR contributes to the failure of chemotherapies in various cancers, including breast, ovarian, lung, gastrointestinal and hematological malignancies. Moreover, the therapeutic efficiency of anticancer drugs or nanoparticles (NPs) used alone is less than that of the combination of NPs and anticancer drugs. Combination therapy has long been adopted as the standard first-line treatment of several malignancies to improve the clinical outcome. Combination therapy with anticancer drugs has been shown to generally induce synergistic drug actions and deter the onset of drug resistance. Therefore, this review is designed to report and analyze the recent progress made to address combination therapy using NPs and anticancer drugs. We first provide a comprehensive overview of the angiogenesis and of the different types of NPs currently used in treatments of cancer; those emphasized in this review are liposomes, polymeric NPs, polymeric micelles (PMs), dendrimers, carbon NPs, nanodiamond (ND), fullerenes, carbon nanotubes (CNTs), graphene oxide (GO), GO nanocomposites and metallic NPs used for combination therapy with various anticancer agents. Nanotechnology has provided the convenient tools for combination therapy. However, for clinical translation, we need continued improvements in the field of nanotechnology.</P>

Antibody–drug conjugates for targeted anticancer drug delivery

김예진,박은지,나동희 한국약제학회 2016 Journal of Pharmaceutical Investigation Vol.46 No.4

Antibody–drug conjugates (ADCs) are tumortargeted therapeutic agents that combine the specificity of monoclonal antibodies (mAbs) with the potent anti-tumor effects of cytotoxic drugs. Over the past few years, ADCs have become a powerful tool in the field of cancer chemotherapy. Recently, two ADC products, brentuximab vedotin (Adcetris) and trastuzumab emtansine (Kadcyla ), have received FDA approval and there are more than 40 ADC candidates in clinical trials for the treatment of various cancers. Despite the success of some products, considerable interests for the next generation of ADCs have focused on the development of homogeneous conjugates because most of the current ADCs are highly heterogeneous with different drug-to-antibody ratios and drug conjugation sites. Recent studies have demonstrated that the site-specific conjugation of drugs to mAbs could produce homogeneous ADC with better pharmacokinetic properties and improved therapeutic index. A number of approaches, including the use of engineered cysteines, the insertion of unnatural amino acids, and enzymatic ligation, have addressed the challenging issues for the synthesis of homogeneous ADC. This review discusses the limitations of current ADC technologies and describes recent site-specific conjugation methods that can be used to prepare homogeneous ADCs for targeted anticancer drug delivery.